CPhI China

April 30, 2010

Continued double digit growth in the Chinese pharmaceutical industry is reflected in record visitor pre-registration levels and a sell-out of exhibition space at this year?s UBM International Media China events - CPhI, ICSE, P-MEC and BioPh.

June 2–4, Shanghai New International Expo Centre

The group of events, which includes ICSE for contract services, P-MEC for Pharma machinery and equipment and BioPh for bio-solutions has become a ‘must attend’ for Western visitors looking to access the many outsourcing and production efficiency partnering opportunities available in China.

Regulatory factors and government investment initiatives provide an additional impetus for Western visitors to gain a foothold in the Chinese market. In November 2008 China announced a major economic stimulus package including $124 bn to be spent on healthcare: clinics, hospitals, pharmacies, insurance and access to medicine.

China is also implementing an “Essential Medicines System” for 2011 which is to make 300–400 essential medicines available to all public facilities, while local GMP standards are being revised in 2010 to be more in line with international ones.

The dramatic expansion of China’s pharma industry is illustrated by the exponential growth experienced by UBM’s portfolio of China events. The inaugural CPhI China in 2001 attracted under 200, mainly domestic exhibitors and 8000 visitors, while this year, the combined events portfolio will host 1,597 Chinese exhibitors and 100 international exhibitors from countries including India, the US, Germany and the UK.

Take your share of the growth in China’s pharma market.

Register for free at www.cphi-china.com